CAS
VRCA icon

Coppell Advisory Solutions’s Verrica Pharmaceuticals VRCA Stock Holding History

Coppell Advisory Solutions’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20
Closed -$140 – 1832
2024
Q4 		$140 Hold
20
– – ﹤0.01% 1867
2024
Q3 		$338 Hold
20
– – ﹤0.01% 1694
2024
Q2 		$1.46K Buy
+20
New +$1.54K ﹤0.01% 1440
2023
Q4 		$1.46K Hold
20
– – ﹤0.01% 1353
2023
Q3 		$550 Hold
20
– – ﹤0.01% 1002
2023
Q2 		$1.15K Buy
+20
New +$1.21K ﹤0.01% 1118
2023
Q1 		– Sell
-20
Closed -$550 – 1066
2022
Q4 		$550 Buy
+20
New +$534 ﹤0.01% 1008

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

Coppell Advisory Solutions's VRCA Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Verrica Pharmaceuticals (VRCA) in Q1 2025, closing a stake of 20 shares — an estimated $140 sold.

Coppell Advisory Solutions first reported a position in VRCA in Q4 2022 and held it in 7 quarters. The position peaked at $1.46K in Q4 2023. 74 funds tracked by Wall St. Rank hold VRCA as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Verrica Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 20 Verrica Pharmaceuticals shares in Q1 2025, an estimated $140.
  • Coppell Advisory Solutions first reported a position in Verrica Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Verrica Pharmaceuticals position peaked at $1.46K in Q4 2023.
  • 74 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.